CVAC vs. VERV, MLYS, KRRO, OLMA, PHAT, ATXS, NUVB, LYEL, GHRS, and ANAB
Should you be buying CureVac stock or one of its competitors? The main competitors of CureVac include Verve Therapeutics (VERV), Mineralys Therapeutics (MLYS), Korro Bio (KRRO), Olema Pharmaceuticals (OLMA), Phathom Pharmaceuticals (PHAT), Astria Therapeutics (ATXS), Nuvation Bio (NUVB), Lyell Immunopharma (LYEL), GH Research (GHRS), and AnaptysBio (ANAB). These companies are all part of the "pharmaceutical preparations" industry.
Verve Therapeutics (NASDAQ:VERV) and CureVac (NASDAQ:CVAC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk, earnings and community ranking.
97.1% of Verve Therapeutics shares are held by institutional investors. Comparatively, 17.3% of CureVac shares are held by institutional investors. 21.4% of Verve Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
CureVac has a net margin of 0.00% compared to CureVac's net margin of -1,701.70%. Verve Therapeutics' return on equity of 0.00% beat CureVac's return on equity.
In the previous week, Verve Therapeutics had 2 more articles in the media than CureVac. MarketBeat recorded 7 mentions for Verve Therapeutics and 5 mentions for CureVac. CureVac's average media sentiment score of 0.56 beat Verve Therapeutics' score of -0.46 indicating that Verve Therapeutics is being referred to more favorably in the media.
Verve Therapeutics has higher earnings, but lower revenue than CureVac.
Verve Therapeutics has a beta of 1.7, suggesting that its share price is 70% more volatile than the S&P 500. Comparatively, CureVac has a beta of 2.51, suggesting that its share price is 151% more volatile than the S&P 500.
CureVac received 5 more outperform votes than Verve Therapeutics when rated by MarketBeat users. Likewise, 53.66% of users gave CureVac an outperform vote while only 44.74% of users gave Verve Therapeutics an outperform vote.
Verve Therapeutics presently has a consensus target price of $33.00, indicating a potential upside of 351.44%. CureVac has a consensus target price of $15.00, indicating a potential upside of 490.55%. Given Verve Therapeutics' higher possible upside, analysts plainly believe CureVac is more favorable than Verve Therapeutics.
Summary
Verve Therapeutics and CureVac tied by winning 8 of the 16 factors compared between the two stocks.
Get CureVac News Delivered to You Automatically
Sign up to receive the latest news and ratings for CVAC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CVAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
